Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study

por Gopal S, Gogate J, Pungor K, Kim E, Singh A, Mathews M
Publicado 2020

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

por Mathews M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S
Publicado 2018

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia

por Lambert M, Sanchez P, Bergmans P, Gopal S, Mathews M, Wooller A, Pungor K
Publicado 2020

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Ho...

por Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, Soares B, Kim E, Savitz AJ
Publicado 2020

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia

por Natalia N. Petrova, Valeria S. Serazetdinova
Publicado 2020

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparat...

por Li HF, Turkoz I, Zhang F
Publicado 2015

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

por Emsley R, Kilian S
Publicado 2018

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability

por Gattaz WF, Saracco-Alvarez R, Daltio CS, Van de Bilt MT, Ortegón JJ, Villaseñor-Bayardo SJ, Louzã M, Elkis H, Soares B, Cabrera Jaramillo P, Lawson F, Díaz-Galvis L
Publicado 2020

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia

por Emsley R, Hargarter L, Bergmans P, Uglešić B, Sengül AC, Petralia A, Khannanova A, Cherubin P, Schreiner A
Publicado 2017

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate

por Such P, Olivares JM, Arias L, Troels Berg M, Madera J
Publicado 2021

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study

por Zhao JP, Li LH, Shi JG, Li Y, Xu XF, Li KQ, Zhang LL, Cai SL, Feng Y, Zhuo JM, Liu WH, Lu HF
Publicado 2017

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia

por Brasso C, Bellino S, Bozzatello P, Montemagni C, Rocca P
Publicado 2017

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

por Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Publicado 2019

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia

por Si T, Zhuo J, Feng Y, Lu H, Hong D, Zhang LL
Publicado 2019

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase II...

por Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ
Publicado 2017

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world cli...

por Di Lorenzo R, Ferri P, Cameli M, Rovesti S, Piemonte C
Publicado 2019